Pharma company has reported significant improvement in overall profitability during the past two quarters.
MUMBAI, Nov 7 (The CONNECT) – Pharma company Innova Captab Limited has reported significant improvement in overall profitability during the past two quarters.
Revenue from Operations was ₹ 318.2 crores in the quarter vs ₹ 282.9 crores last year, registering growth of 12.5% during Q2. EBITDA grew to ₹ 51.9 crores vs ₹ 43.8 crores last year. EBITDA Margins also improved to 16.3% vs 15.5% in Q2 FY24. Profit after Tax improved significantly to ₹ 35.0 crores vs ₹ 22.9 crores (YoY growth of 52.8%). PAT Margins improved to 11.0% from 8.1%
During the first half the current fiscal, Innova Captab’s Revenue from Operations grew 18.7% to ₹ 612.5 crores vs ₹ 516.2 crores during same period in the previous year. EBITDA increased to ₹ 96.2 crores vs ₹ 76.2 crores (YoY improvement of 26.2%). EBITDA margins improved by 90 bps to 15.7%. Profit after Tax grew by 59.2% to ₹ 64.5 crores vs ₹ 40.5 crores in H1 FY24. PAT Margin increased to 10.5% from 7.8%
Vinay Lohariwala, Managing Director – Innova Captab Limited said the company  recently received drug manufacturing license from Jammu and Kashmir state government. With other necessary approvals in place, Innova Captab has already begun manufacturing validation/ trial batches, and the commercialization of the facility is expected within Q3 FY25.
